Neurocrine Biosciences (NBIX) FCF Margin (2010 - 2026)

Neurocrine Biosciences' FCF Margin history runs 16 years deep, the most recent figure standing at 17.73% for Q1 2026.

• Quarterly FCF Margin rose 828.0% year-over-year to 17.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.04% (up 664.0% YoY) and the FY2025 annual result came in at 26.17%, up 252.0% from the prior year.
• FCF Margin was 17.73% for Q1 2026 at Neurocrine Biosciences, down from 48.52% in the prior quarter.
• Across five years, FCF Margin topped out at 700.0% in Q2 2022 and bottomed at 29.92% in Q1 2023.
• A 5-year average of 60.7% and a median of 23.66% in 2023 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin jumped 66501 bps — and 2023, when it tumbled 66037 bps.
• Neurocrine Biosciences' FCF Margin stood at 38.11% in 2022, then sank by 38 bps to 23.66% in 2023, then soared by 38 bps to 32.67% in 2024, then soared by 48 bps to 48.52% in 2025, then slumped by 63 bps to 17.73% in 2026.
• Business Quant data shows NBIX's FCF Margin at 17.73% in Q1 2026, 48.52% in Q4 2025, and 24.28% in Q3 2025.